News | March 01, 2012

Cell>Point Licenses PET/SPECT Cardiac, Cancer Agent for Asia Pacific

March 1, 2012 — Cell>Point announced it entered into a licensing agreement for South Korea, Taiwan, Malaysia, Vietnam and the Philippines with Hyun Imc Co. Ltd., headquartered in Seoul, South Korea, for the kit manufacture, marketing and distribution of Cell>Point’s cancer and cardiology nuclear imaging product.

The product is based on its technetium-99m-labeled ethylenedicysteine-n-acetyl-glucosamine (99mTc-EC-G) radiotracer. Hyun Imc will be responsible for sponsoring clinical studies and seeking regulatory approval in each of the countries covered by the license. Cell>Point will receive an upfront payment, and development and regulatory milestone payments, as well as royalties on gross sales from Hyun Imc.

99mTc-EC-G, invented at the University of Texas MD Anderson Cancer Center and acquired by Cell>Point, is a target-specific molecular imaging radiopharmaceutical that has moved into a Phase 3 lung cancer imaging trial and Phase 2 cardiology imaging trial. It is injected intravenously and then imaged using a single photon emission computed tomography (SPECT) camera.

99mTc-EC-G Phase 3 lung cancer imaging trial

For the Phase 3 lung cancer study, all patients will be imaged on combination SPECT/CT (computerized tomography) and PET/CT cameras. Where combination cameras are not available, a special workstation will be used to integrate the patient images taken from the stand-alone SPECT or PET cameras, as the case may be. Using a workstation to integrate the images allows the medical site to take full advantage of 99mTc-EC-G without the need for a new combination SPECT/CT camera on the premises. This should significantly expand the utilization of the installed SPECT camera base in the United States and the rest of the world, which is already orders-of-magnitude greater than the PET camera base. The lung cancer trial will be followed by Phase 4 trials in lymphoma and breast, liver, colorectal, prostate, and head and neck cancers.

99mTc-EC-G Phase 2 cardiology imaging trial

In a separate clinical trial, 99mTc-EC-G has moved from a Phase 1b to a Phase 2 cardiovascular imaging study. The product is the same as that used in the oncology trials. 99mTc-EC-G exhibits very low uptake in the normal heart; however, it exhibits very high uptake in heart areas that have suffered ischemia (i.e., profound deprivation of blood flow), such as a myocardial infarction. The Phase 2 cardiovascular trial will involve patients who have suspected coronary artery disease and compare 99mTc-EC-G images of the heart with images obtained from a full “stress/rest” myocardial perfusion imaging (MPI) study.

It should be noted that one of the objectives of the study is to compare the results from the “rest” only portion of the 99mTc-EC-G study to the results from the full “stress/rest” MPI study. Based on clinical evidence from the previous Phase 1b study, Cell>Point believes clinical information learned from the 99mTc-EC-G “rest” study will be potentially greater than that of the full “stress/rest” MPI study, which uses 99mTc-sestamibi for the stress image and thallium-201 for the rest image and takes five to seven hours. If the “rest” only 99mTc-EC-G study yields as good as or greater clinical information compared to traditional MPI, then the 99mTc-EC-G rest study—which can be conducted in 30 to 45 minutes — should dramatically improve cardiovascular imaging.

For more information: www.cellpointweb.com

Related Content

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017
The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...
IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017
April 11, 2017 — IBA Molecular announced that it has merged with previous acquisition Mallinckrodt...
GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017
April 5, 2017 — GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered
Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 01, 2017 | Anamika Kumari
Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial r
News | Radiopharmaceuticals and Tracers | January 17, 2017
NorthStar Medical Technologies LLC has received additional matching funds from the U.S. Department of Energy’s National...
SNMMI Develops USP Recommendations for Compounded Sterile Radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | December 28, 2016
December 28, 2016 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has developed United States Pharmac
Overlay Init